

Bilateral Pneumothoraces Following a Right Subclavian Catheter Insertion After Thymectomy for a Patient With a Myasthenic Crisis

Alaa A. Abd-Elseyed, MD, MPH,^{*†} Tamer Ghaly, MD,[‡] Ehab Farag, MD, FRCA,^{†‡}
Wael Ali Sakr Esa, MD, PhD[‡]

^{*}Department of Anesthesiology, University of Cincinnati, Cincinnati, OH

[†]Department of Outcomes Research and

[‡]Department of Anesthesiology, Cleveland Clinic, Cleveland, OH

ABSTRACT

Background: Myasthenia gravis (MG) is an autoimmune disease involving the formation of antibodies against the nicotinic acetylcholine receptors. Thymectomy is the treatment in MG patients with thymoma. We report a case of an MG patient who developed postthymectomy bilateral pneumothoraces after the placement of a subclavian central venous catheter.

Case Report: The 21-year-old patient with MG underwent a thymectomy and, in a later admission, complained of myasthenic crisis symptoms. He was scheduled to receive plasma exchange therapy and electromyography the following day. Plasmapheresis was initiated after the placement of a right subclavian dialysis catheter. Postinsertion chest x-ray revealed bilateral pneumothoraces after a single unilateral attempt to cannulate the right subclavian vein. A right thoracotomy tube was placed with interval resolution of the bilateral pneumothoraces.

Conclusion: The development of bilateral pneumothoraces in this case was attributed to the possible accidental communication between the 2 pleural spaces, which rarely happens during thymectomy surgery.

INTRODUCTION

Myasthenia gravis (MG) is an autoimmune disease characterized by the presence of antibodies directed against the nicotinic acetylcholine receptors or other muscle membrane proteins leading to skeletal muscle weakness. It is estimated that 85% of patients with MG have identifiable antiacetylcholine receptor antibodies that damage the postsynaptic muscle membrane via multiple mechanisms that include complement-mediated reaction, increasing degradation and decreasing the formation of acetylcholine receptors.¹ Myasthenic crisis is a life-threatening complication that occurs in approximately 15% to 20% of patients with MG. Myasthenic crisis is usually associated with pulmonary infection and is also characterized by the development of respiratory failure that requires mechanical ventilation.¹

Thymoma exists in 10%-15% of MG patients, and this group of patients will likely benefit from a thymectomy as it can improve their symptoms.² Pneumothorax is a known complication of central line placement in the chest, and the incidence is reported to be higher with subclavian vein catheterization compared to other central venous lines.³ We present a case of a patient with MG who was treated with thymectomy and then developed bilateral pneumothoraces after a single attempt at placing a subclavian venous catheter.

CASE REPORT

A 21-year-old Caucasian male with a medical history of seropositive MG that was first diagnosed in September 2008 was subsequently treated with thymectomy in November 2008. He presented 1 year later to the intensive care unit at the Cleveland Clinic with myasthenic crisis.

The patient reported that during the prior 4 weeks, he had experienced worsening symptoms. Initially, these symptoms included dysarthria, nasal voice, difficulty swallowing, and occasional ptosis, but no

Address correspondence to
Wael Ali Sakr Esa, MD, PhD
Department of General Anesthesia
Cleveland Clinic Foundation
9500 Euclid Ave., E-31
Cleveland, OH 44195
Tel: (216) 925-2001
Fax: (216) 444-0789
Email: alisakw@ccf.com

Keywords: Central venous catheters, chest tubes, myasthenia gravis, pneumothorax

The authors have no financial or proprietary interest in the subject matter of this article.




Figure. Chest x-ray showing bilateral pneumothoraces.

double vision. Then he began to experience frequent falling that resulted in head trauma and loss of consciousness, excessive salivation, lacrimation, abdominal cramping, and vomiting. The patient stated that his legs “have been giving out.” His home medication included pyridostigmine bromide 60 mg every 4 hours and azathioprine 100 mg in the morning and 150 mg in the evening. Previous mycophenolate therapy had failed. The patient also reported that 2 weeks earlier he had had flu-like illness with fever.

The critical care team was consulted because the patient was progressively deteriorating, with increasing shortness of breath and increasing oxygen requirements. His oxygen saturation was 93% on a 100% nonrebreather mask. Later, the patient was intubated and mechanically ventilated because of

inadequate airway protection and respiratory muscle fatigue. He was scheduled to receive plasma exchange therapy and electromyography on the following day.

Plasmapheresis was initiated after the placement of a right subclavian dialysis catheter, which was placed after a single attempt. Following insertion of the subclavian catheter, a chest x-ray revealed bilateral pneumothoraces. Because we cannulated only the right side and the patient developed bilateral pneumothoraces, we hypothesized that a communication was created between the 2 pleural spaces during the previous thymectomy surgery. We placed a right thoracotomy tube with interval resolution of the bilateral pneumothoraces, confirming our hypothesis about the presence of a communication between the

2 pleural spaces. The patient underwent 6 rounds of plasmapheresis and was successfully extubated. He was then discharged with an oral steroid and appropriate follow-up.

DISCUSSION

MG is treated by 4 basic therapies that include (1) symptomatic treatment by anticholinesterase agents, (2) chronic immunomodulating treatment by glucocorticoids and other immunosuppressive drugs, (3) rapid immunomodulating treatment by plasmapheresis and intravenous immunoglobulins, and (4) surgical treatment by performing thymectomy.⁴

Because there is evidence that the thymus gland plays a role in the pathogenesis of MG, thymectomy is part of the treatment. Most patients with MG have thymic abnormalities such as hyperplasia that is found in 60%-70% and thymoma that is found in 10%-15%. Thus, a computed tomography scan or magnetic resonance imaging of the chest and mediastinum is part of the diagnostic evaluation of all patients with MG.⁵

The thymus gland is a cervicothoracic structure, extending from the inferior border of the thyroid gland to the level of the fourth costal cartilages. A cervicothoracic incision is needed to approach the gland. A median sternotomy or a partial upper sternotomy will also provide sufficient access to the gland.⁶

During surgery, the thymus gland is identified by its characteristic grey-ink color that distinguishes it from the yellow fat of the mediastinum. The dissection begins from below and moves upward in the extracapsular plane. The surgeon makes every effort to avoid entering the pleural space by pushing the mediastinal extensions of each pleural membrane laterally. But if either pleural space is inadvertently entered, no attempt is made to suture and close the defect.⁷

Bilateral pneumothoraces after thymectomy are very rare. We attributed the development of bilateral pneumothoraces in this patient (after a single unilateral attempt to insert a subclavian venous access on the right side) to the communication created between the 2 pleural spaces during his previous thymectomy procedure.

CONCLUSION

Our patient with MG developed bilateral pneumothoraces after the placement of a subclavian venous catheter. The development of bilateral pneumothoraces in this case was attributed to the accidental development of a communication between the 2 pleural spaces during his previous thymectomy surgery.

REFERENCES

1. Palace J, Vincent A, Beeson D. Myasthenia gravis: diagnostic and management dilemmas. *Curr Opin Neurol*. 2001 Oct;14(5):583-589.
2. Kondo K. Optimal therapy for thymoma. *J Med Invest*. 2008 Feb; 55(1-2):17-28.
3. National Institute for Health and Clinical Excellence. Technology Appraisal: The Clinical Effectiveness and Cost Effectiveness of Ultrasonic Locating Devices for the Placement of Central Venous Lines. September 2002. <http://www.nice.nhs.uk/guidance/index.jsp?action=byID&o=11474>. Accessed February 14, 2013.
4. Richman DP, Agius MA. Treatment of autoimmune myasthenia gravis. *Neurology*. 2003 Dec 23;61(12):1652-1661.
5. Jaretzki A, Steinglass KM, Sonett JR. Thymectomy in the management of myasthenia gravis. *Semin Neurol*. 2004 Mar; 24(1):49-62.
6. Jaretzki A 3rd, Wolff M. "Maximal" thymectomy for myasthenia gravis. Surgical anatomy and operative technique. *J Thorac Cardiovasc Surg*. 1988 Nov;96(5):711-716.
7. Nichols FC III, Ercan S, Trastek VF. Standardized thymectomy. In: Shields TW, LoCicero J, Ponn RB, et al, eds. *General Thoracic Surgery*. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:2629-2633.

This article meets the Accreditation Council for Graduate Medical Education and the American Board of Medical Specialties Maintenance of Certification competencies for Patient Care and Medical Knowledge.